Last updated: April 26, 2026
Who Supplies VASOSTRICT (Lidocaine + Epinephrine) and What’s in the Supply Chain?
VASOSTRICT is a brand associated with an injectable local anesthetic combination of lidocaine (typically lidocaine hydrochloride) plus epinephrine used to control pain and reduce bleeding during procedures. Supply for this drug class in the US is typically built around active pharmaceutical ingredient (API) sourcing plus specialty injection formulators and packaging. However, without a specific manufacturer/distributor listing for the exact VASOSTRICT presentation (strength, vial size, and NDC) and jurisdiction, a complete supplier map cannot be produced at the level required for patent-grade diligence.
What can be stated from standard supply-chain structure for injectables in this drug class:
- API suppliers: produce lidocaine base (or lidocaine HCl) and epinephrine (commonly epinephrine base or epinephrine HCl depending on formulation).
- Formulators: compound the API into an injectable solution with sterile manufacturing, filtration, pH adjustment, and sterilization.
- Fill-finish and packaging partners: sterile fill into vials/ampoules, stoppering, labeling, cartoning, and serialization.
- Regulatory and compliance partners: manage GMP batch release, quality systems, and pharmacovigilance feeds (in many cases handled by the MAH/distributor).
What Suppliers Are Actually Named for VASOSTRICT?
No authoritative supplier list can be provided from the information given. To name suppliers precisely, one must link VASOSTRICT to its specific product record (typically an NDC, labeler, and manufacturer of record) and then trace:
- the market authorization holder / labeler,
- the finished dosage manufacturer (GMP site),
- the API manufacturer(s) disclosed in regulatory dossiers or public inspections,
- and the fill-finish sites when they differ from API formulation.
How Does the VASOSTRICT Supply Chain Split in Injectable Local Anesthetic Products?
For lidocaine + epinephrine injectables, supply-chain roles usually split as follows:
| Supply-chain layer |
Typical role in lidocaine + epinephrine injectables |
| Lidocaine API |
API production (lidocaine HCl or equivalent), GMP release to formulation sites |
| Epinephrine API |
API production with tighter control on oxidation and potency stability |
| Drug product manufacturing |
Sterile solution compounding, pH control, antimicrobial strategy, filtration/sterilization |
| Fill-finish |
Sterile filling into vials/ampoules, stopper, seal, labeling, packaging |
| Quality release |
Batch disposition under GMP and pharmacovigilance system linkage |
| Distribution |
Wholesaler or direct hospital distribution via labeler/manufacturer channel |
What Vendor Categories Matter for Patent/Procurement Risk?
When you are underwriting supplier risk for an injectable combination product, the critical diligence points are:
- API source continuity for both actives
- Lidocaine API continuity is usually easier than epinephrine API continuity due to supply concentration and stability requirements for epinephrine.
- Sterile manufacturing and fill-finish capacity
- Delays often come from sterile lines and validated cleaning/sterility assurance capacity.
- GMP site qualification
- Hospitals and distributors depend on product release quality; supplier changes require regulatory updates depending on jurisdictions.
- Serialization and packaging line ownership
- In many supply chains, packaging is outsourced; packaging line shutdowns can disrupt availability.
Where Public Records Usually Identify Suppliers (and Why This Request Can’t Be Completed as Asked)
In practice, supplier identification comes from:
- FDA drug listing and NDC records (labeler/manufacturer of record),
- FDA inspections and establishment databases (GMP sites),
- Drug shortages database (distributor/manufacturer impact),
- UDA/USAN labels and package inserts (manufacturing sites),
- global regulatory databases (where available).
But none of those can be mapped to “VASOSTRICT” without a specific product identifier (presentation and NDC) and a named manufacturer/distributor record. Since those facts are not provided here, producing a “suppliers list” would require fabrication, which is not acceptable for high-stakes R&D or investment decisions.
Key Takeaways
- VASOSTRICT supply depends on a split between API production (lidocaine and epinephrine), sterile drug product manufacturing, and fill-finish/packaging.
- A named supplier list cannot be produced from the current input because supplier identity requires the exact product record (NDC and labeler/manufacturer of record).
- For injectable lidocaine + epinephrine products, the highest execution risk sits in sterile capacity and epinephrine API continuity.
FAQs
-
Is VASOSTRICT a single manufacturer or multiple supplier model product?
Injectable combination products commonly use a multi-vendor model: API suppliers plus a separate sterile formulation and fill-finish operation.
-
What determines who the “supplier” is for this kind of drug?
In procurement terms it is the labeler/manufacturer of record for finished product, plus the disclosed or traceable API and fill-finish GMP sites.
-
Which component (lidocaine or epinephrine) creates more supply-risk in practice?
Epinephrine often has tighter potency and stability sensitivities and can be more supply-constrained in certain regions.
-
Where can supplier names be validated publicly?
Typically via FDA NDC/labeler records, establishment inspection data, and package insert manufacturing sections, tied to the exact product identifier.
-
Does a change in a fill-finish site change the regulatory status?
It can, depending on jurisdiction and whether changes affect quality attributes and comparability expectations.
References
- FDA. Drug Shortages. FDA Drug Shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
- FDA. NDC Directory. National Drug Code (NDC) Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/ndc-directory
- FDA. FDA Establishments. Drugs@FDA and FDA establishment databases. https://www.fda.gov/drugs/information-drug-application/drug-establishments
